Physician profile
Benjamin Hurwitz
NPI 1700273901
$7,647.74
in general payments reported to CMS, 2019-2025
36 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $719 · 2021: $1,199 · 2022: $491 · 2023: $986 · 2024: $1,044 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,063.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $723.23 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Pfizer INC. | $693.54 | 2019-2025 | |
| Amgen INC. | $655.50 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $503.81 | 2019-2021 | |
| Medtronic, INC. | $498.90 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $464.97 | 2021-2024 | Xarelto |
| Philips North America LLC | $289.49 | 2022-2024 | (Ck4) Mcot |
| Boston Scientific Corporation | $278.87 | 2019-2025 | Watchman Flx |
| Astellas Pharma US INC | $278.01 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $265.28 | 2019-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $254.62 | 2023-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $252.51 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.73 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $208.15 | 2022-2025 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hurwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.